Symbols / BYSI
BYSI Chart
About
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 55.93M |
| Enterprise Value | 54.59M | Income | -7.83M | Sales | — |
| Book/sh | -0.79 | Cash/sh | 0.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 40 | IPO | — |
| P/E | — | Forward P/E | -2.89 | PEG | — |
| P/S | — | P/B | -1.73 | P/C | — |
| EV/EBITDA | -7.01 | EV/Sales | — | Quick Ratio | 0.98 |
| Current Ratio | 1.89 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.19 | EPS next Y | -0.47 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 41.12M |
| Shs Float | 31.08M | Short Float | 7.85% | Short Ratio | 47.59 |
| Short Interest | — | 52W High | 3.44 | 52W Low | 0.98 |
| Beta | 0.53 | Avg Volume | 266.24K | Volume | 11.21K |
| Target Price | — | Recom | None | Prev Close | $1.29 |
| Price | $1.36 | Change | 5.43% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.36
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$1.36
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-05-02 | main | Baird | — → Outperform | $1 |
| 2021-12-02 | down | Jefferies | Buy → Hold | $5 |
| 2021-12-02 | down | B of A Securities | Buy → Underperform | $5 |
| 2021-12-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-09-20 | main | HC Wainwright & Co. | — → Buy | $65 |
| 2021-09-09 | init | Baird | — → Outperform | $50 |
| 2021-08-04 | up | HC Wainwright & Co. | Neutral → Buy | $100 |
| 2021-04-05 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-01-11 | init | B of A Securities | — → Buy | $25 |
| 2020-12-29 | init | Evercore ISI Group | — → Outperform | $30 |
| 2020-06-15 | main | HC Wainwright & Co. | — → Buy | $46 |
| 2020-03-30 | main | HC Wainwright & Co. | — → Buy | $30 |
| 2020-02-07 | init | Jefferies | — → Buy | $25 |
| 2020-01-10 | init | Nomura | — → Buy | $34 |
| 2019-12-03 | init | William Blair | — → Outperform | — |
| 2018-06-22 | main | Maxim Group | Buy → Buy | $48 |
| 2017-04-04 | init | Rodman & Renshaw | — → Buy | $43 |
- BeyondSpring (NASDAQ: BYSI) Phase 3 Asian data shows HR 0.69, cuts neutropenia to 3.9% - Stock Titan Fri, 12 Dec 2025 08
- BeyondSpring (NASDAQ:BYSI) Shares Up 2.4% - Here's Why - MarketBeat Wed, 18 Feb 2026 05
- BeyondSpring Shares Rise 2.4% - National Today Sat, 21 Feb 2026 01
- BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade Sat, 13 Dec 2025 08
- BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewswire Mon, 09 Feb 2026 08
- BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative hu, 11 Dec 2025 08
- BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria Fri, 12 Dec 2025 08
- Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - Yahoo Finance ue, 28 Oct 2025 07
- We Think BeyondSpring (NASDAQ:BYSI) Needs To Drive Business Growth Carefully - simplywall.st Wed, 24 Sep 2025 07
- BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan hu, 11 Dec 2025 08
- BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade Fri, 12 Dec 2025 08
- Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 23 Dec 2025 08
- BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView Mon, 15 Dec 2025 08
- Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Yahoo Finance hu, 15 May 2025 07
- BeyondSpring Stock Restarts Its Sprint With A Key Cancer Deal In China - Investor's Business Daily hu, 26 Aug 2021 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 131311 | 227675 | — | Sale at price 1.72 - 1.76 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-17 00:00:00 | I |
| 1 | 13876 | 24720 | — | Sale at price 1.77 - 1.81 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-10 00:00:00 | I |
| 2 | 20200 | 35965 | — | Sale at price 1.76 - 1.79 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-07 00:00:00 | I |
| 3 | 7665 | 13800 | — | Sale at price 1.73 - 1.81 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-02 00:00:00 | I |
| 4 | 1800 | 3045 | — | Sale at price 1.66 - 1.75 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-29 00:00:00 | I |
| 5 | 11772 | 20753 | — | Sale at price 1.68 - 1.83 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-24 00:00:00 | I |
| 6 | 11267 | 19995 | — | Sale at price 1.74 - 1.83 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-19 00:00:00 | I |
| 7 | 4110 | 7603 | — | Sale at price 1.84 - 1.88 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-16 00:00:00 | I |
| 8 | 21046 | 40866 | — | Sale at price 1.90 - 1.97 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-11 00:00:00 | I |
| 9 | 8999 | 17202 | — | Sale at price 1.82 - 1.93 per share. | DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-08 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -20.16K | -26.88K | -90.09K | 62.37K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -8.37M | -14.65M | -35.44M | -64.72M |
| TotalUnusualItems | -96.00K | -128.00K | -429.00K | 231.00K |
| TotalUnusualItemsExcludingGoodwill | -96.00K | -128.00K | -429.00K | 231.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.29M | -13.09M | -33.28M | -64.18M |
| ReconciledDepreciation | 285.00K | 302.00K | 232.00K | 61.00K |
| EBITDA | -8.47M | -14.78M | -35.87M | -64.49M |
| EBIT | -8.75M | -15.08M | -36.10M | -64.55M |
| NetInterestIncome | 59.00K | 322.00K | 178.00K | 11.00K |
| InterestExpense | 0.00 | 17.00K | 87.00K | |
| InterestIncome | 59.00K | 322.00K | 195.00K | 98.00K |
| NormalizedIncome | -3.22M | -12.99M | -32.94M | -64.35M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.12M | -21.03M | -33.28M | -64.18M |
| TotalExpenses | 8.75M | 15.08M | 38.59M | 67.59M |
| TotalOperatingIncomeAsReported | -8.75M | -15.08M | -37.24M | -66.24M |
| DilutedAverageShares | 39.73M | 39.00M | 39.09M | 39.02M |
| BasicAverageShares | 39.73M | 39.00M | 39.09M | 39.02M |
| DilutedEPS | -0.28 | -0.54 | -0.85 | -1.64 |
| BasicEPS | -0.28 | -0.54 | -0.85 | -1.64 |
| DilutedNIAvailtoComStockholders | -11.12M | -21.03M | -33.28M | -64.18M |
| NetIncomeCommonStockholders | -11.12M | -21.03M | -33.28M | -64.18M |
| NetIncome | -11.12M | -21.03M | -33.28M | -64.18M |
| MinorityInterests | 5.57M | 922.00K | 3.00M | 4.03M |
| NetIncomeIncludingNoncontrollingInterests | -16.69M | -21.95M | -36.28M | -68.21M |
| NetIncomeDiscontinuousOperations | -7.83M | -7.93M | ||
| NetIncomeContinuousOperations | -8.87M | -14.02M | -36.28M | -68.21M |
| TaxProvision | 96.00K | 92.00K | 163.00K | 3.57M |
| PretaxIncome | -8.77M | -13.92M | -36.12M | -64.64M |
| OtherIncomeExpense | -74.00K | 836.00K | 944.00K | 1.59M |
| OtherNonOperatingIncomeExpenses | 22.00K | 964.00K | 1.37M | 1.36M |
| GainOnSaleOfSecurity | -96.00K | -128.00K | -429.00K | 231.00K |
| NetNonOperatingInterestIncomeExpense | 59.00K | 322.00K | 178.00K | 11.00K |
| InterestExpenseNonOperating | 0.00 | 17.00K | 87.00K | |
| InterestIncomeNonOperating | 59.00K | 322.00K | 195.00K | 98.00K |
| OperatingIncome | -8.75M | -15.08M | -37.24M | -66.24M |
| OperatingExpense | 8.75M | 15.08M | 38.59M | 67.59M |
| ResearchAndDevelopment | 2.64M | 7.27M | 25.58M | 36.89M |
| SellingGeneralAndAdministration | 6.11M | 7.81M | 13.01M | 30.70M |
| GeneralAndAdministrativeExpense | 6.11M | 7.81M | 13.01M | 30.70M |
| OtherGandA | 6.11M | 7.81M | 13.01M | 30.70M |
| TotalRevenue | 0.00 | 0.00 | 1.35M | 1.35M |
| OperatingRevenue | 0.00 | 0.00 | 1.35M | 1.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 40.32M | 39.03M | 39.00M | 38.93M |
| ShareIssued | 40.32M | 39.03M | 39.00M | 38.93M |
| TotalDebt | 589.00K | 847.00K | 4.96M | 3.58M |
| TangibleBookValue | -32.90M | -26.80M | -5.98M | 26.68M |
| InvestedCapital | -32.90M | -26.80M | -5.98M | 28.25M |
| WorkingCapital | 17.57M | 10.46M | 31.17M | 59.97M |
| NetTangibleAssets | -32.90M | -26.80M | -5.98M | 26.68M |
| CapitalLeaseObligations | 589.00K | 847.00K | 4.96M | 2.01M |
| CommonStockEquity | -32.90M | -26.80M | -5.98M | 26.68M |
| TotalCapitalization | -32.90M | -26.80M | -5.98M | 26.68M |
| TotalEquityGrossMinorityInterest | -14.29M | -23.46M | -3.01M | 26.38M |
| MinorityInterest | 18.61M | 3.34M | 2.97M | -307.00K |
| StockholdersEquity | -32.90M | -26.80M | -5.98M | 26.68M |
| GainsLossesNotAffectingRetainedEarnings | 1.34M | 894.00K | 436.00K | -523.00K |
| OtherEquityAdjustments | 436.00K | -523.00K | ||
| ForeignCurrencyTranslationAdjustments | 1.34M | 894.00K | 436.00K | |
| RetainedEarnings | -407.43M | -396.30M | -375.28M | -342.00M |
| AdditionalPaidInCapital | 373.19M | 368.60M | 368.86M | 369.20M |
| CapitalStock | 4.00K | 4.00K | 4.00K | 4.00K |
| CommonStock | 4.00K | 4.00K | 4.00K | 4.00K |
| TotalLiabilitiesNetMinorityInterest | 48.60M | 48.27M | 49.23M | 55.27M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 37.59M | 40.31M | 41.88M | 40.12M |
| OtherNonCurrentLiabilities | 709.00K | |||
| LiabilitiesHeldforSaleNonCurrent | 6.20M | 7.85M | ||
| PreferredSecuritiesOutsideStockEquity | 5.45M | |||
| EmployeeBenefits | 73.00K | 112.00K | 85.00K | 87.00K |
| TradeandOtherPayablesNonCurrent | 3.61M | 3.59M | 3.58M | 622.00K |
| NonCurrentDeferredLiabilities | 27.40M | 28.17M | 34.22M | 37.94M |
| NonCurrentDeferredRevenue | 27.40M | 28.17M | 34.22M | 37.94M |
| LongTermDebtAndCapitalLeaseObligation | 307.00K | 589.00K | 4.00M | 1.47M |
| LongTermCapitalLeaseObligation | 307.00K | 589.00K | 4.00M | 1.47M |
| CurrentLiabilities | 11.01M | 7.96M | 7.35M | 15.15M |
| OtherCurrentLiabilities | 8.98M | 3.81M | 122.00K | 366.00K |
| CurrentDeferredLiabilities | 1.75M | 1.35M | 1.37M | |
| CurrentDeferredRevenue | 1.75M | 1.35M | 1.37M | |
| CurrentDebtAndCapitalLeaseObligation | 282.00K | 258.00K | 966.00K | 2.11M |
| CurrentCapitalLeaseObligation | 282.00K | 258.00K | 966.00K | 538.00K |
| CurrentDebt | 1.57M | |||
| OtherCurrentBorrowings | 1.57M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 612.00K | 967.00K | 1.33M | 1.80M |
| PayablesAndAccruedExpenses | 1.14M | 2.93M | 3.58M | 9.51M |
| CurrentAccruedExpenses | 840.00K | 2.35M | 2.47M | 3.86M |
| Payables | 296.00K | 579.00K | 1.11M | 5.65M |
| TotalTaxPayable | 1.00K | 18.00K | 32.00K | 4.00M |
| IncomeTaxPayable | 16.00K | 3.57M | ||
| AccountsPayable | 295.00K | 561.00K | 1.08M | 1.66M |
| TotalAssets | 34.31M | 24.81M | 46.22M | 81.65M |
| TotalNonCurrentAssets | 5.74M | 6.39M | 7.70M | 6.53M |
| OtherNonCurrentAssets | 4.87M | 5.32M | 339.00K | 271.00K |
| NonCurrentAccountsReceivable | 113.00K | 18.00K | 8.00K | 1.30M |
| NetPPE | 752.00K | 1.05M | 7.35M | 4.95M |
| AccumulatedDepreciation | -554.00K | -482.00K | -551.00K | -319.00K |
| GrossPPE | 1.31M | 1.53M | 7.90M | 5.27M |
| Leases | 271.00K | 272.00K | 272.00K | 274.00K |
| ConstructionInProgress | 0.00 | 1.54M | ||
| OtherProperties | 624.00K | 843.00K | 6.98M | 2.99M |
| MachineryFurnitureEquipment | 411.00K | 414.00K | 648.00K | 458.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 28.58M | 18.42M | 38.52M | 75.12M |
| OtherCurrentAssets | 68.00K | 168.00K | 763.00K | 1.02M |
| AssetsHeldForSaleCurrent | 25.35M | 2.62M | ||
| RestrictedCash | 0.00 | 9.94M | 0.00 | |
| PrepaidAssets | 240.00K | 292.00K | 492.00K | 1.74M |
| CashCashEquivalentsAndShortTermInvestments | 2.92M | 5.40M | 37.27M | 72.37M |
| OtherShortTermInvestments | 193.00K | 2.87M | 30.74M | |
| CashAndCashEquivalents | 2.92M | 5.40M | 34.40M | 41.62M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.67M | -16.57M | -28.18M | -50.09M |
| RepaymentOfDebt | 0.00 | -1.57M | 0.00 | |
| IssuanceOfDebt | 3.91M | 0.00 | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 3.00M | 0.00 | 0.00 | 0.00 |
| CapitalExpenditure | -224.00K | -100.00K | -34.00K | -2.84M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 17.00K | 91.00K |
| IncomeTaxPaidSupplementalData | 7.00K | 36.00K | 367.00K | 22.00K |
| EndCashPosition | 2.92M | 15.34M | 34.40M | 41.62M |
| OtherCashAdjustmentOutsideChangeinCash | -13.12M | -2.41M | ||
| BeginningCashPosition | 17.75M | 34.40M | 41.62M | 109.54M |
| EffectOfExchangeRateChanges | -33.00K | -76.00K | -756.00K | -258.00K |
| ChangesInCash | -1.67M | -16.57M | -6.47M | -67.65M |
| FinancingCashFlow | 26.79M | 4.00K | 3.43M | 1.00K |
| CashFlowFromContinuingFinancingActivities | 26.79M | 4.00K | 3.43M | 1.00K |
| NetOtherFinancingCharges | 19.87M | 5.00M | -82.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 4.00K | 0.00 | 83.00K |
| NetCommonStockIssuance | 3.00M | 0.00 | 0.00 | 0.00 |
| CommonStockIssuance | 3.00M | 0.00 | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 3.91M | 0.00 | -1.57M | 0.00 |
| NetLongTermDebtIssuance | 3.91M | 0.00 | -1.57M | 0.00 |
| LongTermDebtPayments | 0.00 | -1.57M | 0.00 | |
| LongTermDebtIssuance | 3.91M | 0.00 | 0.00 | 0.00 |
| InvestingCashFlow | -12.01M | -100.00K | 18.25M | -20.41M |
| CashFlowFromContinuingInvestingActivities | -12.01M | -100.00K | 18.25M | -20.41M |
| NetOtherInvestingChanges | -687.00K | |||
| NetInvestmentPurchaseAndSale | -11.79M | 0.00 | 17.56M | -17.57M |
| SaleOfInvestment | 1.00M | 1.30M | 49.76M | 26.66M |
| PurchaseOfInvestment | -12.79M | -1.30M | -32.20M | -44.23M |
| NetPPEPurchaseAndSale | -224.00K | -100.00K | 683.00K | -2.84M |
| SaleOfPPE | 0.00 | 717.00K | 0.00 | |
| PurchaseOfPPE | -224.00K | -100.00K | -34.00K | -2.84M |
| OperatingCashFlow | -16.44M | -16.47M | -28.15M | -47.24M |
| CashFlowFromContinuingOperatingActivities | -16.44M | -16.47M | -28.15M | -47.24M |
| ChangeInWorkingCapital | -2.99M | 3.28M | 6.41M | 18.41M |
| ChangeInOtherWorkingCapital | -1.00M | 249.00K | -1.35M | 30.03M |
| ChangeInOtherCurrentLiabilities | -804.00K | -823.00K | -3.19M | 2.69M |
| ChangeInOtherCurrentAssets | -181.00K | 2.64M | 11.58M | -13.32M |
| ChangeInPayablesAndAccruedExpense | -994.00K | 437.00K | -1.96M | -2.27M |
| ChangeInAccruedExpense | -387.00K | 111.00K | -1.39M | -1.71M |
| ChangeInPayable | -607.00K | 326.00K | -575.00K | -560.00K |
| ChangeInAccountPayable | -607.00K | 326.00K | -575.00K | -560.00K |
| ChangeInPrepaidAssets | -9.00K | 779.00K | 1.33M | 1.27M |
| ChangeInReceivables | 0.00 | |||
| OtherNonCashItems | 702.00K | 1.09M | 912.00K | -89.00K |
| StockBasedCompensation | 2.25M | 770.00K | 1.67M | 3.15M |
| UnrealizedGainLossOnInvestmentSecurities | -3.00K | -4.00K | -19.00K | -144.00K |
| DepreciationAmortizationDepletion | 285.00K | 302.00K | 232.00K | 61.00K |
| DepreciationAndAmortization | 285.00K | 302.00K | 232.00K | 61.00K |
| Depreciation | 285.00K | 302.00K | 232.00K | 61.00K |
| OperatingGainsLosses | 37.00K | -1.07M | -422.00K | |
| GainLossOnInvestmentSecurities | -1.07M | -444.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 37.00K | 0.00 | 22.00K |
| NetIncomeFromContinuingOperations | -16.69M | -21.95M | -36.28M | -68.21M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BYSI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|